Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:ARWR NASDAQ:CYTK NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$21.54+1.5%$22.45$12.72▼$31.77$2.66B1.521.88 million shs1.12 million shsARWRArrowhead Pharmaceuticals$73.86+1.1%$71.42$14.30▼$82.26$10.30B1.281.56 million shs1.20 million shsCYTKCytokinetics$67.90-5.0%$70.06$31.99▼$80.20$8.89B0.421.92 million shs2.38 million shsKRYSKrystal Biotech$301.76+0.3%$283.40$127.99▼$319.48$8.87B0.53242,920 shs259,664 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%-1.07%+0.28%-14.46%+47.74%ARWRArrowhead Pharmaceuticals0.00%-6.19%+0.54%+20.47%+334.80%CYTKCytokinetics0.00%-6.88%-7.06%+14.51%+121.30%KRYSKrystal Biotech0.00%-2.60%-1.54%+16.37%+119.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$21.54+1.5%$22.45$12.72▼$31.77$2.66B1.521.88 million shs1.12 million shsARWRArrowhead Pharmaceuticals$73.86+1.1%$71.42$14.30▼$82.26$10.30B1.281.56 million shs1.20 million shsCYTKCytokinetics$67.90-5.0%$70.06$31.99▼$80.20$8.89B0.421.92 million shs2.38 million shsKRYSKrystal Biotech$301.76+0.3%$283.40$127.99▼$319.48$8.87B0.53242,920 shs259,664 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%-1.07%+0.28%-14.46%+47.74%ARWRArrowhead Pharmaceuticals0.00%-6.19%+0.54%+20.47%+334.80%CYTKCytokinetics0.00%-6.88%-7.06%+14.51%+121.30%KRYSKrystal Biotech0.00%-2.60%-1.54%+16.37%+119.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0057.85% UpsideARWRArrowhead Pharmaceuticals 2.75Moderate Buy$87.8018.87% UpsideCYTKCytokinetics 2.86Moderate Buy$99.3046.24% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.117.41% UpsideCurrent Analyst Ratings BreakdownLatest ARQT, ARWR, CYTK, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/20/2026ARWRArrowhead Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)5/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$99.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy5/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/13/2026ARWRArrowhead Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$35.00 ➝ $46.005/12/2026CYTKCytokinetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $97.005/11/2026CYTKCytokinetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$136.00 ➝ $140.005/8/2026ARWRArrowhead Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $87.005/7/2026ARQTArcutis Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.005/7/2026CYTKCytokinetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$95.00 ➝ $105.00(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$415.62M6.48N/AN/A$1.55 per share13.90ARWRArrowhead Pharmaceuticals$829.45M12.54$0.12 per share612.14$3.64 per share20.29CYTKCytokinetics$105.82M79.85N/AN/A($5.39) per share-12.60KRYSKrystal Biotech$417.30M21.32$7.31 per share41.29$42.06 per share7.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$16.14M-$0.03N/A22.44N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)ARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)CYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.3428.68N/A53.92%19.25%17.62%8/3/2026 (Estimated)Latest ARQT, ARWR, CYTK, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.542.682.46ARWRArrowhead Pharmaceuticals1.416.236.23CYTKCytokineticsN/A4.214.21KRYSKrystal BiotechN/A9.469.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AARWRArrowhead Pharmaceuticals62.61%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%ARWRArrowhead Pharmaceuticals3.60%CYTKCytokinetics2.60%KRYSKrystal Biotech13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableARQT, ARWR, CYTK, and KRYS HeadlinesRecent News About These CompaniesBNP Paribas Financial Markets Has $13.29 Million Stock Holdings in Krystal Biotech, Inc. $KRYSJune 8 at 3:21 AM | marketbeat.comIs Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?June 7 at 1:51 PM | insidermonkey.comNorges Bank Acquires New Shares in Krystal Biotech, Inc. $KRYSJune 7 at 5:19 AM | marketbeat.comSuma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) StockJune 7 at 4:13 AM | americanbankingnews.comInsider Selling: Krystal Biotech (NASDAQ:KRYS) Insider Sells 25,000 Shares of StockJune 6 at 7:26 AM | insidertrades.comIs the Options Market Predicting a Spike in Krystal Biotech Stock?June 5 at 1:00 PM | zacks.comKrystal Biotech Stock Soars 16% in Three Months: Here's WhyJune 4, 2026 | zacks.comWhy Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?June 3, 2026 | zacks.comH.C. Wainwright Sticks to Their Buy Rating for Krystal Biotech (KRYS)June 2, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)June 2, 2026 | theglobeandmail.comFisher Asset Management LLC Invests $933,000 in Krystal Biotech, Inc. $KRYSMay 31, 2026 | marketbeat.comKrystal Biotech (NASDAQ:KRYS) EVP John Charles Thomas Sells 642 SharesMay 28, 2026 | insidertrades.comHere's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum StockMay 26, 2026 | zacks.comEpidermolysis Bullosa: New Therapies Target Genetics, Wound HealingMay 25, 2026 | medscape.comMWilliam Blair Investment Management LLC Has $92.78 Million Stock Holdings in Krystal Biotech, Inc. $KRYSMay 24, 2026 | marketbeat.comCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallMay 21, 2026 | globenewswire.comKrystal Biotech, Inc. $KRYS Stake Boosted by Handelsbanken Fonder ABMay 21, 2026 | marketbeat.comTimesSquare Capital Management LLC Cuts Position in Krystal Biotech, Inc. $KRYSMay 20, 2026 | marketbeat.comAtle Fund Management AB Sells 8,338 Shares of Krystal Biotech, Inc. $KRYSMay 20, 2026 | marketbeat.comPittsburgh Biotech's Gene Gel Wins UK Green Light for DEB WoundsMay 19, 2026 | hoodline.comHKrystal Biotech gains regulatory approval to sell gene therapy in the United KingdomMay 19, 2026 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARQT, ARWR, CYTK, and KRYS Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$21.54 +0.31 (+1.46%) Closing price 04:00 PM EasternExtended Trading$21.28 -0.26 (-1.23%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Arrowhead Pharmaceuticals NASDAQ:ARWR$73.86 +0.77 (+1.05%) Closing price 04:00 PM EasternExtended Trading$73.29 -0.57 (-0.77%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Cytokinetics NASDAQ:CYTK$67.90 -3.58 (-5.01%) Closing price 04:00 PM EasternExtended Trading$67.95 +0.05 (+0.07%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$301.76 +0.76 (+0.25%) Closing price 04:00 PM EasternExtended Trading$307.00 +5.24 (+1.74%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look Amprius Insiders Are Selling: Should Investors Be Worried? MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Planet Labs: Coming Back Down to Earth Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
